News from vanda pharmaceuticals inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Mar 04, 2015, 16:31 ET

Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis

 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced top-line results of the Phase II proof of concept clinical study...

Feb 19, 2015, 07:00 ET

Vanda Pharmaceuticals Reports Fourth Quarter 2014 and Full Year 2014 Financial Results

 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced financial and operational results for the fourth quarter and full year...

Feb 02, 2015, 19:00 ET

Vanda Pharmaceuticals to Announce Fourth Quarter 2014 Financial Results on February 19, 2015

 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products...

Jan 29, 2015, 19:00 ET

Vanda Pharmaceuticals to Participate in the Canaccord Genuity Rare Disease, Biopharma One-on-One Day

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the...

Jan 16, 2015, 09:30 ET

Vanda Announces Listing of a New Fanapt® Patent in the FDA Orange Book

 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that a Fanapt® patent, number 8,586,610 ('610 patent), is now listed in...

Dec 22, 2014, 16:01 ET

Vanda to regain US and Canadian rights to Fanapt®

 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that it has reached a settlement agreement with...

Dec 01, 2014, 20:30 ET

Vanda Pharmaceuticals to Present at the 26th Annual Piper Jaffray Healthcare Conference

 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products...

Nov 18, 2014, 09:45 ET

Vanda Pharmaceuticals to Present at the Stifel Nicolaus 2014 Healthcare Conference

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of...

Oct 29, 2014, 09:00 ET

Vanda Pharmaceuticals Inc. Prices Public Offering of Common Stock

WASHINGTON, Oct. 29, 2014 /PRNewswire/ – Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced the sale of 5,000,000...

Oct 28, 2014, 16:01 ET

Vanda Pharmaceuticals Inc. Proposes Public Offering of Common Stock

 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that it intends to offer and sell shares of its common stock in an...

Oct 27, 2014, 07:00 ET

Vanda Pharmaceuticals Reports Third Quarter 2014 Financial Results

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced financial and operational results for the third quarter ended September 30,...

Oct 14, 2014, 07:00 ET

Vanda Pharmaceuticals to Announce Third Quarter 2014 Financial Results on October 27, 2014

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the...

Aug 07, 2014, 07:00 ET

Vanda Pharmaceuticals Reports Second Quarter 2014 Results

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the...

Jul 17, 2014, 19:00 ET

Vanda Pharmaceuticals to Announce Second Quarter 2014 Financial Results on August 7, 2014

 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products...

Jun 03, 2014, 07:00 ET

European Medicines Agency Accepts HETLIOZ™ (tasimelteon) Marketing Authorization Application for Non-24-Hour Sleep-Wake Disorder in the Totally Blind

 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) announced today that its Marketing Authorization Application (MAA) for oral...

Jun 02, 2014, 19:00 ET

HETLIOZ™ (tasimelteon) Data in Patients with Non-24-Hour Sleep-Wake Disorder to be presented at SLEEP 2014 meeting

 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) will present additional data from its HETLIOZ™ (tasimelteon) clinical development...

May 29, 2014, 21:00 ET

Vanda Pharmaceuticals to Present at the Jefferies 2014 Global Healthcare Conference

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the...

May 08, 2014, 07:00 ET

Vanda Pharmaceuticals Reports First Quarter 2014 Results

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the...

Apr 24, 2014, 17:30 ET

Vanda Pharmaceuticals to Announce First Quarter 2014 Financial Results on May 8, 2014

 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products...

Apr 09, 2014, 19:00 ET

Vanda Pharmaceuticals Announces Availability of HETLIOZ™ (tasimelteon) for Non-24-Hour Sleep-Wake Disorder (Non-24)

 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced the availability of HETLIOZ™.  HETLIOZ™ is the first...